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Stem celldevelopment and maintenance of many tissues. This is due to their capacity for
extensive proliferation and differentiation into effector cells. More recently it has been shown that the
proliferative and differentiative ability of stem cells decreases with age, suggesting that this may play a role
in tissue aging. Down syndrome (DS), is associated with many of the signs of premature tissue aging
including T-cell deﬁciency, increased incidence of early Alzheimer-type, Myelodysplastic-type disease and
leukaemia. Previously we have shown that both hematopoietic (HSC) and neural stem cells (NSC) in patients
affected by DS showed signs of accelerated aging. In this study we tested the hypothesis that changes in gene
expression in HSC and NSC of patients affected by DS reﬂect changes occurring in stem cells with age. The
proﬁles of genes expressed in HSC and NSC from DS patients highlight pathways associated with cellular
aging including a downregulation of DNA repair genes and increases in proapoptotic genes, s-phase cell cycle
genes, inﬂammation and angiogenesis genes. Interestingly, Notch signaling was identiﬁed as a potential hub,
which when deregulated may drive stem cell aging. These data suggests that DS is a valuable model to study
early events in stem cell aging.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionStem cells are central to the development, maintenance and repair
of all tissues. This is due to their capacity for extensive proliferation
and differentiation into multiple effector cells. The fact that aging is
accompanied by a diminished capacity to adequately maintain tissue
homeostasis has suggested that a decline in stem cell function may be
central to the process of tissue aging.
Indeed stem cells from several tissues have been shown to
functionally decline with advancing age. In hematopoietic stem cells
(HSC) this is manifested with a decreased competitive repopulating
ability, a skewing of lineage potential from lymphopoiesis to
myelopoiesis [1]. This is thought to contribute to the loss of immune
function [2], increased incidence of leukaemia [3] and onset of
anaemia [4] occurringwith age. Similarly neural stem cells (NSC) have
been shown to be reduced in numbers and proliferative potential in
the subventricular zone and in dentate gyrus of the hippocampus withit of Bone Biology, Faculty of
10 2RX, UK. Tel.: +44 114 2711
ono).
ll rights reserved.age [5–7]. Moreover diminished neurogenesis has been observed in
the olfactory bulb of old mice [5], where NSC migrate and contribute
to neurogenesis. Neurogenesis is thought to be important for sensory
and cognitive functions such as memory and learning [8], and
therefore NSC aging has been linked to the decline of those activities
in older people.
Understanding genes and their interactions leading to stem cell
aging is vital to open up opportunities for drug discovery and
strategies to identify compounds capable of extending tissue survival
and repair. Preventive targeting of relatively young stem cells, which
show predisposition to an accelerated aging is more likely to be
successful rather than targeting of aged stem cells which have
undergone profound and complex changes and unlikely to be reverted
by any intervention. Given that aging is considered a continuous
process starting early in development and occurring at different pace
in each individual the identiﬁcation of when and whose stem cells
require intervention is difﬁcult but key to the design of any therapy.
We have previously identiﬁed Down syndrome (DS) as a model to
study early events occurring in stem cells with age. DS is associated
with many of the signs of premature tissue aging including early
abnormalities typical of Alzheimer disease (AD), T-cell deﬁciency,
increased incidence of Myelodysplastic-type disease and leukaemia
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thanks to the presence of trisomy 21.We have shown that stem cells in
DS show signs of premature aging. Mean telomere restriction
fragment length (mTRF) of peripheral blood lymphocytes declines
more rapidly in individuals with DS than in normal individuals
reﬂecting an accelerated HSC telomere shortening [14]. The acceler-
ated telomere shortening is already present in fetal life and is
associated with stem cell deﬁciency as shown by a reduction in cells
possessing the phenotype of HSC (detected as CD34+ cells) in fetal
blood and bone marrow (BM) of DS children and in the number of
long term culture initiating cells in their BM [14]. Moreover NSC
derived from the cortical tissue of DS fetuses at 17–19 weeks of
gestation show severely reduced replicative capacity and early loss of
neuronal differentiation capacity after 10 weeks in culture [15].
In this study we have used HSC and NSC from patients affected by
DS at very early stages of development, to identify early changes in
gene expression occurring in HSC and NSC with age. Using a
combination of genomic analysis and mathematical modelling, we
have identiﬁed a dysregulation of the Notch/Wnt pathway and
showed that changes in DS stem cells reﬂected molecular events
occurring in stem cells of older people. These data are consistent with
the hypothesis that DS is an invaluable model to determine theFig.1. Representative example of the gating strategy used to obtain PI−/CD45+/CD34+/CD
contained in the R1 regionwere plotted and CD45+ cells (leucocyte cells) were further selec
and a R3 region was drawn around the lymphocyte population; (D) The cells common to all
population was identiﬁed (R4) and sorted; (E) CD34+ CD38− population after sort; (F) CDmolecular markers predisposing to stem cell aging and is suitable to
unveil new molecular targets for intervention.
2. Materials and methods
2.1. Sample collection and cell separation
Following a protocol approved by the local research ethics
committees and in agreement with the Helsinki declaration of 1975,
bone marrow was obtained from the iliac crest of DS children (1–
5 years) with no clinical hematological abnormalities undergoing
cardiac surgery and from age matched hematologically healthy
children during similar signiﬁcant surgery following parental consent.
Bone marrow was also collected from individuals 60–80 years old
clear from any hematological malignancy. Long term hematopoietic
stem cells were isolated by labelingmononuclear cells with CD45 APC,
CD34 PE and CD38 FITC (BD biosciences) according to manufacturer's
instructions. CD45+CD34+CD38− (200–1000 cells) were sorted on
FACS Aria sorter (Becton Dickenson) following the addition of
propidium iodide (10 μg/ml, Fluka) to exclude dead cells. The gating
strategy used is represented in Fig. 1. Purity was assessed at the end of
the sort whenever cell numbers allowed and was found to be N95%.38−HSC. (A) A region for live bonemarrow cells (PI negative) was drawn (R1); (B) Cells
ted in the R2 region; (C) The cells contained in both the R1 and R2 regions were plotted
three regions were plotted for CD34 and CD38 expression and the CD34+ and CD38−
34+ CD38+ population after sort. The purity was measured and found to be N95%.
Table 1
Primers' sequence used for RT-qPCR
Gene Forward Reverse
EGR1 GTGATGCGCCTTGCTGATG CTCCCTGCCCCCCTTAAG
IL8 TCCTAGTTTGATACTCCCAGTC ATTGACTGTGGAGTTTTGGC
KLF4 AGCCTAAATGATGGTGCTTGGT CCTTGTCAAAGTATGCAGCAGTTT
JAG1 TCACTGTTTAGATTTGCCATAGAGTACA ATAAGCCTTTTTGATCTTGAACTTCGT
Beta cat TGGACAGTTTACCAGTTGCCTTT TAACCGCATTTTCTCTTGAAGCA
c-Fos TGTACTGTAGTTTTTCTTCAACATCAATG TTCATGGAAAACTGTTAATGTCAGAAC
Smad2 GGATGCAGACCCTGTTCTTGTT TAATATCTCCATCACAGTGCACCAA
DAB2 TGCAAATGAGGGAAGAACATTATTC GGAGCAAAACTGACTGAAAAAAGAA
P21 CAGCGACCTTCCTCATCCA CCTTGTTCCGCTGCTAATCAA
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Birth Defects Laboratory at the University of Washington, Seattle and
the Tissue Bank for Developmental Disorders at the University of
Maryland. Neurospheres were generated from two trisomy 21 cortex
samples and two gestationally agematched controls (12 and 18 weeks
gestation). The method of collection conformed to the guidelines
recommended by National Institutes of Health for the collection of
such tissues and set out by the University of Washington, the
University of Maryland and the University of Wisconsin, Madison.
Institutional Review Board approval was obtained for all of these
studies. Cortical precursors isolated from fetal brain were induced to
proliferate as free-ﬂoating neurospheres [16]. Brieﬂy, freshly isolated
tissue was mechanically chopped and seeded into ﬂasks. The cells
were initially expanded in DMEM/Ham's F12 media with penicillin,
streptomycin, amphotericin B (PSA, 1%) and supplemented with B27
(2%; Life Technologies) and mitogens: EGF (20 ng/ml; Sigma), and
FGF-2 (20 ng/ml; R & D Systems) with heparin (5 μg/ml). Mediawere
replenished every 3–4 days. Neurospheres were passaged every
14 days by a chopping method that does not require trypsin or
mechanical dissociation, and cell–cell contact was continuously
maintained [16]. After 2 weeks, neurospheres were grown in
DMEM/Ham's F12 media with penicillin, streptomycin, amphotericin
B (PSA, 1%) and supplemented with N2 (1%; Life Technologies) and
20 ng/ml EGF.
2.2. PolyA RT-PCR
A total of 200–1000 HSC or NSC were directly lysed in cell lysis
buffer and PolyA RT-PCR was carried out. Global ampliﬁcation of cDNA
corresponding to all expressed genes (polyA PCR) was carried out as
previously reported [17]. Control samples in absence of reverse
transcriptase were also generated.
2.3. Microarray analysis
cDNA samples obtained from 200 cells were labeled using
EpiLabel™ (Epistem, UK) developed by Brady et al. [17,18] and
hybridisided to the Affymetrix HU133 plus 2.0 chip (Affymetrix).
Microarray analysis was carried out at the Paterson Institute for
Cancer Research microarray facility. Background levels, intensities of
spike hybridisation controls were within the acceptable range for all
samples. The percentage of present calls was 25.2±3.0% for HSC and
37.6±1.5% for NSC. Quality controls can be viewed at http://
bioinformatics.picr.man.ac.uk/vice/StartRegistration.vice.
2.4. Data analysis
Normalization was carried out by using the Simpleaffy implemen-
tation [18]. The dendogram was generated based on Pearson
correlation scores and hierarchical clustering using Bioconductor
(Stats package, http://www.bioconductor.org/).
Identiﬁcation of age related genes was carried out based on the
hypothesis that DS samples show accelerated aging when compared
to normal samples and that aging is a continuous process with
changes, which start early in development and increase with time.
Since the NSC cells are from a much earlier stage of development, a
simple model to explain the differences between HSC samples and
NSC samples was built as
ΔXHSC−NSC =Δ+ e
where X is the gene expression level, the ﬁrst term on the right hand
side is the difference due to the different developmental stages, and
the second term includes various sources of noise (including the fact
that the samples come from different tissues). Under the hypothesis
that DS is a model for accelerated aging, we use the difference in ΔXbetween normal and DS samples to detect candidate markers for
aging. We empirically estimated the variance of α=ΔXDS−ΔXN and
selected probes exhibiting a signal to noise ratio greater than 2
equivalent to a p-value of 0.05.
Transcriptional regulation and pathway analysis was performed
using Metacore software (GeneGo Inc.). Analysis of transcriptional
networks was performed using the transcriptional regulation network
building algorithm. This algorithm generates subnetworks centred on
transcription factors, which regulate the most number of genes on the
input list. All positive and negative interactions frommanually curated
published data were included in the analysis.
Gene interaction subnetworks of the Notch signaling pathway
containing high numbers of differentially expressed probes were
analysed using the MMG tool [19, 20]. Brieﬂy, MMG searches the
network for coherently expressed subnetworks by employing a
statistical technique, the Markov Random Field. This essentially
encodes the intuitive idea that a gene interacting with many
differentially expressed genes is more likely to be differentially
expressed. Genes with a probability of being differentially expressed
greater than 80% are assigned to the differentially expressed class, and
subnetworks are then obtained by exhaustive percolation search.
2.5. Real time quantitative PCR
PCR primer pairs were designed for mRNA sequence within 500 bp
of the 3′ end of each gene (Table 1) using Primer Express Software
(Perkin Elmer/Applied Biosystems) and used in PCR reactions carried
out in 10 μl containing qPCR Mastermix for Sybr Green I (Eurogentec),
0.1 μM reverse and forward primers and 2 μl of 1:100 or 1:1000
dilution of PolyA cDNA. PCR was performed using the following
thermal cycle: 2 min 50 °C, 10 min at 95 °C, followed by 40 cycles of
15 s at 95 °C, 60 s at 60 °C. Samples were analysed using an ABI Prism
7700 sequence detection system (PE Applied Biosystems) as recom-
mended by the manufacturer. A dilution series of human genomic
standards for calibration of real-time PCR was generated using human
genomic DNA (Promega). Only primers with an efﬁciency coefﬁcient
of−3.3 to−3.8 were considered. The expression level of the L32 gene
was used to normalize for differences in input of polyA ampliﬁed
cDNA. Each sample was run in triplicate and a RT-PCR negative control
was also tested to exclude any contaminating DNA ampliﬁcation. The
expression ratio was calculated using the standard curve method and
calculating amounts for each sample normalized to L32 amounts.
Differences were considered signiﬁcant with Pb0.05 following non
parametric one way ANOVA Kruskal Wallis test.
3. Results
3.1. Selection of differentially expressed genes
The ability of HSCs to permanently reconstitute myeloablated
recipients in all blood cell lineages is the most rigorous criteria for
evaluating HSC activity. In human, the long-term reconstituting HSC
reside within the CD34+/CD38- fraction of cells in the BM [21]. Total
Fig. 2. Cluster dendrogram of gene expression of NSC and HSC from patients affected by
DS and age matched controls. Data clustered by Pearson correlation and hierarchical
clustering.
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affected by DS but with no apparent hematological abnormalities
(HSC-DS n=2) and healthy age matched controls, (HSC, n=3) was
ampliﬁed. Neurosphere cultures derived from the cortex of primary
human DS fetal tissue (NSC-DS, n=2) at 12 and 18 weeks gestation
respectively, before neuroanatomical defects are observed, and age
matched healthy controls (NSC, n=2) were established. Total RNA
from 200 cells was used for ampliﬁcation before any change in their
growth kinetic and differentiation capacity had ensued and gene
expression proﬁling carried out by Affymetrix gene chip.
Hierarchical clustering of the samples using the expression proﬁles
of all genes showed clustering between the two different cell types
(Fig. 2). Moreover samples obtained from healthy donors had similar
expression patterns and clustered together but were separate fromFig. 3. Biological process networks overrepresented in the shortlist of genes upregulated (ora
Enrichment analysis was performed in Metacore pathway-mapping software. Log of P-value
being associated with each network by chance.samples obtained from donors affected by DS, suggesting differences
between healthy controls and patients affected by DS in both stem cell
types, although those differences were not very pronounced.
Gene expression data from all samples were combined according
to themodel described inMaterials andmethods to detect age-related
differential expression. Under an assumption of Gaussian noise on the
log expression levels, we identiﬁed possible up and downregulated
genes by considering those whose expression levels in the two
conditions differed by more than three standard deviations (esti-
mated from the data under normal assumptions). With this analysis
we have found 430 genes which were differentially expressed, 192
genes were downregulated and 238 upregulated. Of these, 149
upregulated genes (Supplementary data Table 1) and 103 down-
regulated genes (Supplementary data Table 2) had known informa-
tion on function, regulation and interactionwith other genes. We used
this selected shortlist for further analysis.
Analysis of the shortlist of differential genes in terms of biological
function using the manually curated pathway analysis software
Metacore revealed 30 statistically overrepresented networks (Fig. 3).
Most of the pathways listed have been previously associated with
aging. One mechanism believed to be central to the aging of cells is
DNA damage (Fig. 2, process n3) [22]. The downregulation of genes
involved in DNA repair (FANCM, Sirtuins and DNA polymerase eta)
suggests that stem cells from patients affected by DS are more
susceptible to accumulation of DNA damage. Depending on the extent
of the damage, the DNA lesions arising in the stem cells have the
potential to drive cells into senescence or apoptosis. Indeed the
upregulation of proapoptotic genes Grim19 and Ft1 or iTRAF, which
blocks the antiapoptotic function of TRAF proteins implies an
imbalance in the apoptotic process in favour of cell death (Fig. 3,nge) and downregulated (blue) in Down syndrome compared to age matched controls.
s represent the probability of a given number of upregulated and downregulated genes
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cell cycle (Fig. 3, process n. 24) and genes of the Notch pathway (Fig. 3,
process n. 9), known to promote self-renewal [23], suggests the
possibility of stem cells undergoing compensative proliferation. The
presence of numerous pathways involved in inﬂammation is highly
intriguing and in line with very recent data where two biomarkers of
human aging, chitinase and CRAMP,were identiﬁed in themTERC−/−
mouse model of telomere dysfunction and DNA damage and then
validated further in the serum of patients with chronic diseases and
telomere shortening [24]. These proteins are involved during
activation of innate immunity and inﬂammatory disease and suggest
that the immune system may be activated by DNA damage and
contribute to the clearance of apoptotic or senescent cells. Of interestTable 2
Signiﬁcant transcriptional networks associated with the highest number of genes differe
matched controls
Transcriptional network Processes G sco
c-Myc Regulation cell cycle 58.94
SP-1 Senescence, DNA damage,
differentiation of HSC
56.95
P53 Tumor suppression, senescence 56.95
ESR1 (nuclear) Regulation of mitosis and survival 54.90
Androgen receptor Regulator of Notch, Wnt, p53 54.90
C/EBP beta Modulation of cell cycle, T and B cell
development, senescence
52.76
HIF1A Blood vessel development, directly interact
with Notch, regulation of telomerase
50.54
STAT3 Early response to cytokine and inﬂammation,
promotes HSC self-renewal under stimulated
conditions, regulator of hTERT expression
50.54
RelA (p65 NK-kB subunit) Positive regulation of Notch signalling 48.22
STAT1 Retention of balanced hematopoiesis 45.78
GCR-alpha Regulator of transcription 45.78
c-Jun Apoptosis, cell growth and differentiation 43.21
P63 Stem cell proliferation, differentiation,
senescence, regulator of Notch
37.57
FOXO3A Regular cellular resistance to stress, trigger
DNA repair, regulate HSC self-renewal
34.42
Runx2 Regulator of bone commitment 34.42
C/EBPalpha Myeloid development, growth arrest 30.98
P73 Positive regulation of Notch signalling,
regulation of telomerase
30.98
ETS1 Stem cell development, cell senescence
and death, tumorigenesis
30.98
Progesterone receptor Bone remodelling 27.14
NF-AT1 (NFATC2) Control T cell activation 27.14
Elk-1 Induction of immediate early gene
response (i.e. Fos, EGR1), senescence
27.14
c-Fos Positive regulation of Notch signaling,
cell growth, differentiation, transformation
27.14
PU.1 Myeloid cell differentiation, B and T cell
development, HSC maintenance
27.14
SF1 Adrenal gland development 22.75
c-Jun/c-Fos Tumorigenesis, modulator of apoptosis,
cell growth,
differentiation
22.75
HMGI/y Regulator of transcription 22.75
NF-kB1 (p50) Inﬂammation, apoptosis 22.75
E2F1 Cell proliferation, apoptosis,
cell differentiation
22.75
NUR77 Apoptosis, transformation 22.75
STAT5A Self-renewal of HSC, maintenance
of normal and leukaemic stem cells
22.75
P value for each network indicates the probability of assembly from a random set of genes.and surprising at ﬁrst is the strong enrichment in genes involved in
angiogenesis such as IL8, VEGF, amphiregulin, angiogenin, Jagged1 or
HIF1 [25–27]. All of these genes have been described as major players
in changing the tumor microenvironment to enhance the survival and
proliferation of tumor cells [25–28]. It is tantalizing to speculate that
stem cells are capable of changing their own niche through secretion
of factors which increase neovascularisation to suit their survival and
proliferative needs. Overall these data suggest a model where stem
cells in DS showed decreased ability to repair damage, with
consequent accumulation of DNA damage leading to enhanced
apoptosis and establishment of an inﬂammatory and highly vascu-
larised environment. The remaining stem cells undergo increased
proliferation in a cytokine rich environment to compensate losses.ntially expressed in stem cells of patients affected by DS compared to healthy age
re P value Molecules in the network
1.43−37 KLF4, EMP1, DEC2, PDK1, D52, Tiam1, EDG1, CD44, Versican,
NDRG1, EGR1, ID2, C/EBPdelta, NOXA, MDM2, CG4853
3.33−35 EGR1, FasL, SLC39A8, LIPA. eNOS, KLF4, MGF. BMP2,
Alpha-1D adrenergic receptor, PAI2, GLSL, MDM2, LATS2,
BACE1, C/EBPdelta, CYP1B1
3.33−35 Noxa, LTS2, MDM2, AL4A1, eIFSA, Thrombospondin,
galactin-3, SCD, KLF4, Brca2, NDRG1, Versican, EGR1,
DNA polymerase beta, MDR1
7.71−33 Rab-31, Thrombospondin 1, Amphiregulin, RNF32, gp130,
HERC6, NOXA, OCTN2, CYP1B1, Fra-2, C/EBPdelta, MDM2,
LATS2, MDR1. BMP2
7.71−33 IL-8, EGR1, NDRG1, Caspase-2, LATS2, MDM2, PGAR, NOXA,
TMF1, Brca2, Versican, VIL2, Sry, CDK11
1.77−30 KLF4, cEBPbeta, IRF9, HSP90 beta, BP1, GLSL, IL8, FasL, EGR1,
Calgranulin, MDR1, ID2, Fra-2
4.02−28 EGR1, MDR1, ID2, BACE1, MGF, PDK1, DEC2, MCT4, eNOS,
MDM2, LATS2, IL-8, BMAL2
4.02−28 eNOS, NDUFA13, I-TAC, Relaxin 2, C/EBPdelta, HSP90beta,
FasL, IL-8, gp130, TMF1, BACE1, SYCP3
9.04−26 EGR1, MDR1, Il8, PAI2, KLF-4, jagged1, MDM2, MGF, CD44, FasL
2.01−23 KLF4, IRF9, BACE1, MDM2, gp130, Caspase-2, SP100, HSP90,
C/EBPdelta, FasL
2.01−23 HSP90 beta, Relaxin 1, NURR1, Relaxin 2, TR-beta1, MGF, IL-8,
FasL, EGR1, NOR1
4.41−21 eNOS, jagged1, thrombospondin, PAI2, FASL, EGR1, IL8, MDR1,
C/EBPdelta
2.02−16 LATS2, MDM2, Jagged1, AIM2, RGS13, C/EBPbeta, CD44
4.22−14 eNOS, FasL, TANK, KLF4, MDM2, LATS2, MDR1
4.22−14 RGS2, Galectin-3, C/EBPdelta, ID2, EGR1, MDR1
8.56−12 EGR1, GPD1, BP1, C/EBPdelta, Annexin 1
8.56−12 EGR1, MDR1, jagged1, MDM2, LATS2
8.56−12 IL-8, SUMO-3, eNOS, MEIS1, SP100, MDR1
1.68−9 TR-beta2, Relaxin 2, Relaxin 1
1.68−9 FasL, MDM2, LATS2, BACE1
1.68−9 EGR1, ID2, SUMO-3, eNOS
1.68−9 IL-8, EGR1, VIL2, Jagged1
1.68−9 EGR1, ID2, KLF4, BPI
3.16−7 CYP1B1, Sry, EGR1
3.16−7 IL-8, SUMO-3, CD44
3.16−7 EGR1, MGF, CD44
3.16−7 FasL, HBXAP, IL-8
3.16−7 NOXA, MDM2, LATS2
3.16−7 FLAD1, EGR1, Fra-2
3.16−7 TR-beta1, Relaxin 2, Brca2
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Table 3
Subnetworks identiﬁed using the MGG tool
Gene Probe ID α=ΔXDS−ΔXN
Network 1
MAPK14 211087_x_at −2.52
JUN 203752_s_at −1.77
FOS 218880_at −6.83
FRZB 203697_at −2.44
PTEN 211711_s_at −2.23
ARNT 218222_x_at −5.84
EPAS1 200878_at −3.17
HIF1A/HIF 200989_at −1.72
CTNNB1 201533_at −2.20
DVL 57532_at −1.70
FZD 204451_at −2.76
WNT 208570_at −3.61
SFRP4 204051_s_at −2.04
DAB2 201280_s_at −4.12
SMAD4 202527_s_at −2.25
SMAD2 201280_s_at −2.36
VEGFA 210512_s_at −3.13
EP300 202221_s_at −1.82
JAG1 231183_s_at −5.56
RBPJ 211974_x_at −2.35
HEY1 218839_at −2.80
Network 2
ERBB2 222473_s_at −2.31
ERBB3 226213_at −4.63
GRB2 215075_s_at −2.62
SHC1 214853_s_at −1.27
SOS 1557354_at −2.70
Network 3
HRAS 219984_s_at 2.15
RAF1 1557675_at 2.90
BRAF 206044_s_at 1.90
MAP3K1 214786_at 3.50
MAP2K3 215498_s_at 2.31
MAP2K7 216206_x_at 4.14
MAPK8 213014_at 3.69
p53 223920_s_at 2.92
MYC 216188_at 3.16
Network 4
ERBB4 206794_at 2.57
NRG1 208241_at 3.72
EGF 206254_at 3.77
TGFA 211258_s_at 2.19
EGFR 211607_x_at 3.77
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Transcription factors are the major players in governing stem cell
self-renewal and differentiation and as such may constitute the
master regulators of the aging-related expression proﬁle. However
due to the low level of their expression or to the modiﬁcation
occurring at the post-translational level during their activation, they
are often lost by microarray analysis. To overcome this problem we
used the transcriptional regulation network mapping algorithm
within Metacore to search for the transcription factors which regulate
the highest number of genes present in the differentially expressed
gene shortlist. This analysis highlighted 30 signiﬁcant transcriptional
networks (Table 2), which identiﬁes important key regulators of stem
cell aging in patients affected by DS and is in agreement with our
analysis of biological process involvement. Transcription factors
important in aging and senescence such as c-myc (Fig. 4a), p53 (Fig.
4b) and c/EBPbeta (Fig. 4c) regulated the highest number of genes on
the differential list and as such were among the most signiﬁcant
networks [29–31]. NF-kB (RelA) (Fig. 4d), NF-AT1 and HIF-1 alpha are
transcriptional networks involved in inﬂammation and/or angiogen-
esis [27, 32–34]. Moreover NF-kB is also activated by increased
intracellular ROS [35] suggesting that stem cells may be subjected to
increased damage. Indeed the dysregulation of FOXO3A is in support
of this. FOXO3A has recently been shown to be important in the
preservation of long-term HSC reserve and function with age by
protecting them from ROS damage [36].
Of the 30 signiﬁcant networks 10 were related to Notch signaling
(p53, c-Myc, HIF1A, p63, p73, RelA, c-Jun, c-Fos, STAT3, E2F1) an
important regulator of stem cell numbers in vitro and in vivo and
known to promote self-renewal [23, 37]. As transcription factors
related to Notch were the most represented we then searched using
the direct interactions network building algorithm within Metacore
for known positive and negative direct interactions among the genes
involved in all 10 transcriptional networks and identiﬁed the novel
network represented in Fig. 4e. This network is enriched for genes
present on the differentially expressed gene shortlist and shows a
great deal of connectivity between the various Notch-related
transcription factor networks. As such it represents an interesting
model of the signaling pathways underlying the aging proﬁle
generated from the differential gene list and a biological framework
on which to further investigate stem cell aging and self-renewal.
3.3. Notch subnetwork analysis
From our previous pathway and transcriptional network analysis
Notch signaling has emerged as an important player. To further
identify the altered subpathway involved in the accelerated aging of
stem cells in DS with age we integrated data on direct interactions
among genes of the Notch pathway, provided by Metacore, with the
expression data using the MMG tool as described above. The key idea
underlying this is that integrating network structure should yield a
more informative way of detecting the differential expression state of
genes. The input for the model was the values of α=ΔXDS−ΔXN for
the 161 genes involved in the pathway. The output of themodel is a set
of posterior probabilities of regulation class for the genes: 47 genes
had posterior probability greater than 0.8 of being up-regulated in DS,
and 28 had posterior probability greater than 0.8 of being down-
regulated in DS. Percolation analysis of the network revealed four
coherently regulated subnetworks (two up-regulated and two down-
regulated); the genes involved in these networks, as well as theirFig. 4. Transcriptional regulation of the shortlist of genes up and downregulated in Down s
regulated by A— c-myc, B — p53, C — C/EBP alpha and D— RelA transcription factors. E — Di
networks related to Notch: RelA, p53, c-fos, p73, p63, c-jun, c-myc, HIF1A, STAT3 and E2F1. Th
patients, while those with a blue circle were downregulated. Green lines indicate positive in
out according to their sub-cellular location.Affymetrix probe IDs and their fold changes (values of α), are listed in
Table 3 and represented in Fig. 5.
Overall the subnetwork analysis supports the model suggested by
the analysis of the biological processes. Increased proliferation is
suggested by most networks. Activation of HIF1A and VEGF is in line
with the transcriptional network analysis and reinforces the concept
of increased neovascularisation of the microenvironment as an
autocrine mechanism to improve survival and proliferation. Similarly
the increase in the expression of ErbB-2 has been shown to be
associated with recruitment of progenitor cells during the cell-cycle
[38]. Most important is the upregulation of key molecules belonging
to Notch,WNTand TGFbeta pathways, all shown to be involved in self-
renewal of HSC and NSC [39]. Indeed the cooperation between WNT
and Notch has recently been reported as important for HSC
maintenance [40] and molecules such as beta catenin and Smad4
have been shown to have a role in HSC maintenance and self-renewalyndrome compared to age matched controls. Transcriptional networks showing genes
rect interactions network showing connectivity between genes in the 10 transcriptional
e genes represented with a red solid circle were found to be upregulated in HSC from DS
teractions, while red lines indicate negative interactions. Network objects are separated
Fig. 5. Representation of signiﬁcant subnetworks in the notch pathway. “Signal transduction_Notch signaling” GeneGo process static network drawn in Metacore and overlayed with
genes from the 4 signiﬁcant subnetworks described in Table 3. Connectivity between genes involved in these subnetworks is represented by blue lines. The genes represented with a
red solid circle were found to be upregulated in HSC-DS (networks 1 and 2 in Table 3), while those with a blue circle were downregulated (networks 3 and 4 in Table 3).
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prevent HSC differentiation and promote proliferation leading to
higher levels of chimerism in transplantation [41]. Smad4 deﬁcient
HSC displayed a signiﬁcantly reduced repopulation capacity in
primary and secondary recipients, suggesting that increased levels
promotes HSC self-renewal [42]. A decrease in c-myc and p53
expression seen in network 3 (Table 3) is in favour of preservation
of the stem cell pool either by blocking differentiation [43] or
increasing proliferation [44]. However, increased DNA damage
accompanied by increased proliferation potentially poses a danger
for malignant transformation especially in a cytokine rich environ-
ment. Indeed it has been shown that mice with a reduced expression
of p53 showed an increase in the HSC pool but also an increase in the
incidence of tumorigenesis [44]. It is possible that a decrease of genes
such as Pten [45] or increase of p38MAPK [46] is put in place as censor
mechanisms to block the rise of potentially malignant clones by
inducing apoptosis or senescence.
3.4. Validation of DS as model of stem cell aging
To test whether changes in expression seen in stem cells of patients
affected by DS reﬂected changes in stem cells of older people we
performed quantitative RT-PCR (qRT-PCR) on key genes present on
either or both of the networks identiﬁed by transcriptional analysis
and MGG analysis (represented in Figs. 4 and 5). We compared
expression in PI−/CD45+/CD34+/CD38− HSC of hematologically
healthy 1–5 years old donors (n=7) with expression in HSC of age
matched patients affected by DS (n=4) and 60–80 year old donors
(n=9). According to the developmental model of aging, changes in
expression were expected to be greater when comparing HSC of
younger and older donors. Only two genes, PAI2 and LATS, were
upregulated in DS but not in HSC of older people. All the remaininggenes tested are shown in Fig. 6 and follow the same trend in HSC of
patients affected by DS and HSC of older donors. Of interest is that the
changes in expression in HSC of patients affected by DSwere mostly at
intermediate levels between the expression levels of HSC in younger
and older healthy donors.
The disadvantage of this method is that it is only able to account for
positive interactions and therefore pathways are expected not to be
exhaustive. Indeed p21 an important gene of the pathway, which
senses telomere attrition and block cell proliferation in response to
telomere dysfunction was found upregulated in the expression array
but did not emerge by any of the network analyses. The upregulated
expression was conﬁrmed by realtime qPCR on independent DS HSC
and HSC of older people, conﬁrming that further work is required for
the complete identiﬁcation of the pathways involved. These data
suggests that DS detects early events occurring in stem cells with age
and that age is an incremental process that starts during fetal
development and continues throughout life. Notch and Wnt are
important in the process of human stem cell aging but some data are
missing and are for further study.
4. Discussion
This study shows how a systems biology approach based on
modelling of the process of stem cell aging and strengthened by
information on direct protein interactions in networks and pathways
can overcome some of the limitations imposed by previous gene
expression analysis and lead to the identiﬁcation of a stem cell aging
signature.
To date gene expression studies of human stem cells had been
carried out to identify a stem cell self-renewal signature but failed in
their intention [47–49]. The limitation of those studies is in the
analysis based on simple bioinformatics and comparison of gene lists
Fig. 6. Genes which are differentially expressed in DS follow the same pattern in HSC of older people. Realtime qPCR for the expression of KLF4, IL8, EGR1, JAG1, FOS, DAB2, Beta
catenin, SMAD2, p21 in PI−/CD45+/CD34+/CD38− cells from hematologically healthy younger donors (1–5 years old), patients affected by DS (1–5 years old) and hematologically
healthy older donors (60–80 years old). P values are indicated when statistical signiﬁcance was reached by ANOVA.
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to select the differentially expressed genes our study considers a
model of aging whereby all stem cells in a pool have similar properties
and gradually and co-ordinately change over time during develop-
ment and aging. The model predicts that DS patients changes in NSC
(fetal stem cells) are smaller than those seen in HSC (adult stem cells)
due to their earlier stage of development. Moreover, to enrich for
biologically signiﬁcant processes we have considered only the
differentially expressed genes of known function and used experi-
mental information on connectivity between proteins, their subunits
and DNA sequences. In this way we were able to identify key
transcription factors, independently of post-translational modiﬁca-
tion, and important subpathways involved in the accelerated aging of
stem cells of patients affected by DS.
The data obtained show strength in a variety of ways. There is
great consistency of the results among the different analyses carried
out. Transcriptional networks and subnetworks identify molecules
which overlap and are central to processes related to aging. Most
importantly key genes identiﬁed by our analysis were also identiﬁed
by two other studies in a different progeroid syndrome, the
Hutchinson Guilford Progeroid Syndrome, and in a different stem
cell type, the mesenchymal stem cell [50,51], highlighting how thesepathways are well conserved among stem cell types and across
accelerated aging disorders and may well be the core molecules of an
aging stem cell signature. Although most of the genes we have
identiﬁed are not included in the differentially expressed genes
identiﬁed in HSC of older mice by bioinformatic analysis [1], mining
of the same data for individual genes such as c-Fos, KLF4 and IL8
showed upregulation of these genes in mice with age, suggesting that
those networks may well be conserved between human and mice
and a similar signature could be found if the same mathematical
model was applied.
We have focused the validation of DS as a model of stem cell aging
to the analysis of HSC due to their easier availability from older donors
where, according to the model, changes were expected to be the
greatest. We have shown that 9/11 genes tested and expected to be
overexpressed in HSC of patients affected by DS were also up-
regulated by HSC of older people. These data suggest that overall
changes in HSC of patients affected by DS reﬂect changes in HSC of
older people. As predicted by the mathematical model those changes
were even greater in HSC of older donors than in HSC of patients
affected by DS because they occurred in a later phase of development,
in line with a model of continuous development of the aging process
and with DS as a model of early changes in aging.
362 C.J. Cairney et al. / Biochimica et Biophysica Acta 1792 (2009) 353–363This study supports the attempt to preserve the stem cell pool by
upregulation of genes active in enhancing proliferation or inhibiting
differentiation to compensate for losses due to increased damage,
apoptosis and senescence. However, in agreement with the view that
advancing age is accompanied by an increased incidence of cancer and
that stem cells represent the ideal target for the accumulation of
premalignant damage, it also supports the notion of a tenuous balance
between tumor suppression and stem cell aging. There are several
elements which suggest that the compensative proliferative stress
may put the stem cell at higher risk of neoplastic transformation. The
decrease in p53 levels may signal a stem cell which is predisposed to
malignant transformation. p53+/− mice showed an increase in HSC
numbers but also an increase in the incidence of cancer [44]. Decrease
Pten levels have been associated with the generation of leukaemia
initiating cells [45]. Active NK-kB has been found to correlate with
proinﬂammatory cytokine and proangiogenic factors to form an
environment favourable to survival and proliferation but also to
malignant transformation [33,52]. On the other hand factors such as
C/EBPbeta have been shown to decrease proliferation and induce
senescence in response to oncogenic stimuli to restrict the expansion
of incipient neoplastic cells, leading to activation of multiple
interleukins such as IL8 [31]. Indeed IL8 expression has been seen to
increase 1000 fold in response to oncogenic stimuli [31]. The presence
of tumor suppressor mechanisms triggered by telomere dysfunction,
such as those mediated by the increase of p21, seems to counter-
balance the oncogenic potential of the aged stem cell and its
environment. However any failure of those mechanisms may ﬁnd
favourable conditions for cancer development.
In summary this is the ﬁrst study to identify key genes and
processes occurring in human stem cells with age and validates Down
syndrome as an excellent model to detect early events in aging of stem
cells. It is the ﬁrst time that molecules such as p38MAPK, FOXO3A and
p21, which have been shown to have a role in stem cells with age using
artiﬁcial murine knock out models, do play a role in the regulation of
HSC of older individuals in physiological conditions. Identiﬁcation of
upregulation of molecules such as p21 provides hope that aging may
be delayed without concomitant increase in cancer incidence by the
careful manipulation of the p21 pathway in stem cells as shown in
murine models [53].
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